Cargando…

Analysis of Nephrolithiasis Treatment in Highest Reference Hospital—Occurrence of Acromegaly in the Study Group

Background: Urolithiasis is one of the most common diseases of the urinary system, the incidence of which is assumed to be up to 100,000 cases per million (10% of the population). The cause of it is dysregulation of renal urine excretion. Acromegaly is a very rare endocrine disorder that causes a so...

Descripción completa

Detalles Bibliográficos
Autores principales: Ząbkowski, Tomasz, Durma, Adam Daniel, Grabińska, Agnieszka, Michalczyk, Łukasz, Saracyn, Marek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299108/
https://www.ncbi.nlm.nih.gov/pubmed/37373574
http://dx.doi.org/10.3390/jcm12123879
_version_ 1785064282600243200
author Ząbkowski, Tomasz
Durma, Adam Daniel
Grabińska, Agnieszka
Michalczyk, Łukasz
Saracyn, Marek
author_facet Ząbkowski, Tomasz
Durma, Adam Daniel
Grabińska, Agnieszka
Michalczyk, Łukasz
Saracyn, Marek
author_sort Ząbkowski, Tomasz
collection PubMed
description Background: Urolithiasis is one of the most common diseases of the urinary system, the incidence of which is assumed to be up to 100,000 cases per million (10% of the population). The cause of it is dysregulation of renal urine excretion. Acromegaly is a very rare endocrine disorder that causes a somatotropic pituitary adenoma producing higher amounts of growth hormone. It occurs approximately in 80 cases per million (about 0.008% of the population). One of the acromegaly complications may be urolithiasis. Methods: Clinical and laboratory results of 2289 patients hospitalized for nephrolithiasis in the highest reference hospital were retrospectively analyzed, distinguishing a subgroup of patients with acromegaly. Statistical analysis was performed to compare the prevalence of the disease in the analyzed subgroup with the epidemiological results available in up-to-date literature. Results: The distribution of nephrolithiasis treatment was definitely in favor of non-invasive and minimally invasive treatment. The methods used were as follows: ESWL (61.82%), USRL (30.62%), RIRS (4.15%), PCNL (3.1%), and pyelolithotomy (0.31%). Such a distribution limited the potential complications of the procedures while maintaining the high effectiveness of the treatment. Among two thousand two hundred and eighty-nine patients with urolithiasis, two were diagnosed with acromegaly before the nephrological and urological treatment, and seven were diagnosed de novo. Patients with acromegaly required a higher percentage of open surgeries (including nephrectomy) and also had a higher rate of kidney stones recurrence. The concentration of IGF-1 in patients with newly diagnosed acromegaly was similar to those treated with somatostatin analogs (SSA) due to incomplete transsphenoidal pituitary surgery. Conclusions: In the population of patients with urolithiasis requiring hospitalization and interventional treatment compared to the general population, the prevalence of acromegaly was almost 50-fold higher (p = 0.025). Acromegaly itself increases the risk of urolithiasis.
format Online
Article
Text
id pubmed-10299108
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102991082023-06-28 Analysis of Nephrolithiasis Treatment in Highest Reference Hospital—Occurrence of Acromegaly in the Study Group Ząbkowski, Tomasz Durma, Adam Daniel Grabińska, Agnieszka Michalczyk, Łukasz Saracyn, Marek J Clin Med Article Background: Urolithiasis is one of the most common diseases of the urinary system, the incidence of which is assumed to be up to 100,000 cases per million (10% of the population). The cause of it is dysregulation of renal urine excretion. Acromegaly is a very rare endocrine disorder that causes a somatotropic pituitary adenoma producing higher amounts of growth hormone. It occurs approximately in 80 cases per million (about 0.008% of the population). One of the acromegaly complications may be urolithiasis. Methods: Clinical and laboratory results of 2289 patients hospitalized for nephrolithiasis in the highest reference hospital were retrospectively analyzed, distinguishing a subgroup of patients with acromegaly. Statistical analysis was performed to compare the prevalence of the disease in the analyzed subgroup with the epidemiological results available in up-to-date literature. Results: The distribution of nephrolithiasis treatment was definitely in favor of non-invasive and minimally invasive treatment. The methods used were as follows: ESWL (61.82%), USRL (30.62%), RIRS (4.15%), PCNL (3.1%), and pyelolithotomy (0.31%). Such a distribution limited the potential complications of the procedures while maintaining the high effectiveness of the treatment. Among two thousand two hundred and eighty-nine patients with urolithiasis, two were diagnosed with acromegaly before the nephrological and urological treatment, and seven were diagnosed de novo. Patients with acromegaly required a higher percentage of open surgeries (including nephrectomy) and also had a higher rate of kidney stones recurrence. The concentration of IGF-1 in patients with newly diagnosed acromegaly was similar to those treated with somatostatin analogs (SSA) due to incomplete transsphenoidal pituitary surgery. Conclusions: In the population of patients with urolithiasis requiring hospitalization and interventional treatment compared to the general population, the prevalence of acromegaly was almost 50-fold higher (p = 0.025). Acromegaly itself increases the risk of urolithiasis. MDPI 2023-06-06 /pmc/articles/PMC10299108/ /pubmed/37373574 http://dx.doi.org/10.3390/jcm12123879 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ząbkowski, Tomasz
Durma, Adam Daniel
Grabińska, Agnieszka
Michalczyk, Łukasz
Saracyn, Marek
Analysis of Nephrolithiasis Treatment in Highest Reference Hospital—Occurrence of Acromegaly in the Study Group
title Analysis of Nephrolithiasis Treatment in Highest Reference Hospital—Occurrence of Acromegaly in the Study Group
title_full Analysis of Nephrolithiasis Treatment in Highest Reference Hospital—Occurrence of Acromegaly in the Study Group
title_fullStr Analysis of Nephrolithiasis Treatment in Highest Reference Hospital—Occurrence of Acromegaly in the Study Group
title_full_unstemmed Analysis of Nephrolithiasis Treatment in Highest Reference Hospital—Occurrence of Acromegaly in the Study Group
title_short Analysis of Nephrolithiasis Treatment in Highest Reference Hospital—Occurrence of Acromegaly in the Study Group
title_sort analysis of nephrolithiasis treatment in highest reference hospital—occurrence of acromegaly in the study group
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299108/
https://www.ncbi.nlm.nih.gov/pubmed/37373574
http://dx.doi.org/10.3390/jcm12123879
work_keys_str_mv AT zabkowskitomasz analysisofnephrolithiasistreatmentinhighestreferencehospitaloccurrenceofacromegalyinthestudygroup
AT durmaadamdaniel analysisofnephrolithiasistreatmentinhighestreferencehospitaloccurrenceofacromegalyinthestudygroup
AT grabinskaagnieszka analysisofnephrolithiasistreatmentinhighestreferencehospitaloccurrenceofacromegalyinthestudygroup
AT michalczykłukasz analysisofnephrolithiasistreatmentinhighestreferencehospitaloccurrenceofacromegalyinthestudygroup
AT saracynmarek analysisofnephrolithiasistreatmentinhighestreferencehospitaloccurrenceofacromegalyinthestudygroup